<DOC>
	<DOCNO>NCT00122304</DOCNO>
	<brief_summary>The primary objective evaluate safety eculizumab patient transfusion-dependent hemolytic PNH</brief_summary>
	<brief_title>Study Safety Hemolytic Paroxysmal Nocturnal Hemoglobinuria ( PNH ) Patients Treated With Eculizumab</brief_title>
	<detailed_description />
	<mesh_term>Hemoglobinuria , Paroxysmal</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<criteria>PNH &gt; 6 month Type III PNH red blood cell ( RBC ) clone flow cytometry &gt; 10 % At least one transfusion past 2 year 3 transfusion past 12 month ; personal belief preclude use transfusion severe hemolytic PNH Lactate dehydrogenase ( LDH ) &gt; 1.5 x upper limit normal Must avoid conception Willing able give write informed consent Platelet count &lt; 30,000/mm3 Absolute neutrophil count &lt; 500/ul Active bacterial infection Hereditary complement deficiency History bone marrow transplantation Participation investigational drug trial exposure investigational agent , device procedure within 30 day Pregnant , breastfeeding , intend conceive History meningococcal disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
</DOC>